Showing 7 posts of 7 posts found.


MSD’s Keytruda improvess overall survival in Phase 3 oesophageal cancer

November 15, 2018
Research and Development Cancer, MSD, PD-L1, keytruda, pharma

MSD has announced new Phase 3 data on its anti-PD-1 therapy Keytruda (pembrolizumab) as a second-line treatment for advanced or …


Roche’s Tecentriq meets primary endpoints in Phase III lung cancer trial

September 1, 2016
Research and Development PD-L1, Roche, keytruda, nivolumab, opdivo, phase III, tecentriq

Roche has presented new Phase III data for cancer immunotherapy Tecentriq (atezolizumab), which shows a clinically meaningful improvement in overall …


MSD says Phase III trials for Keytruda to treat advanced melanoma shows better survival

June 8, 2016
Research and Development ASCO, MSD, Merck & Co, PD-L1, advanced melanoma, drug trial, immuno-oncology, keytruda

Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced melanoma showed over half …

Keytruda image

MSD’s Keytruda impresses in lung cancer chemotherapy trial

December 21, 2015
Manufacturing and Production, Research and Development MSD, PD-L1, docetaxel, keytruda, lung cancer, non small cell lung cancer, non-small cell lung cancer, pd-1, pembrolizumab

MSD’s Keytruda significantly improved overall survival (OS) compared to chemotherapy in people with lung cancer and PD-L1 expression, a trial …


Roche posts positive mid-stage trial results for atezolizumab

July 13, 2015
Research and Development Genentech, PD-L1, Phase II, Roche, anti-PD-L1, atezolizumab, clinical trial, immuno-oncology, personalised medicine

A cancer drug in development by Roche has performed well in a mid-phase clinical trial – prompting the Swiss firm …

Merck image

Merck seeks new Keytruda indication in US

April 20, 2015
Sales and Marketing Cancer, FDA, NSCLC, PD-L1, US, keytruda, lung, pembrolizumab

Merck is seeking FDA approval for its successful melanoma drug Keytruda to be used treating lung cancer. The Supplemental Biologics …

Pfizer signs $3 billion cancer deal

November 18, 2014
Research and Development, Sales and Marketing Cancer, Merck KGaA, PD-L1, Pfizer, anti-PD-L1, opdivo

Pfizer has signed a multi-billion dollar deal to develop one of Merck KGaA’s investigational drugs, MSB0010718C, an anti-PD-L1 antibody. The …

Latest content